For patients with known CNS metastases at baseline, lorlatinib may potentially offer better CNS disease control, albeit with more toxicity relative to brigatinib/alectinib. Brigatinib is more convenient in terms of dosing from the patient perspective (one tablet once daily versus up to four twice da...

There are multiple therapeutic options for patients with ALK rearranged non-small cell lung cancer. We now have 3 phase 3 trials that have shown that next generation ALK directed therapy is superior to crizotinib for advanced adenocarcinoma patients harboring an ALK rearrangement. Alectinib, Brigati...

There is no head to head data that suggest superiority of alectinib over brigatinib or vice versa, nor are those data likely to become available. Both have demonstrated significant (and similar) PFS gains over crizotinib and both are associated with significant CNS activity in terms of time to CNS p...

I use alectinib because the data is more mature, experience, and there are no cross trial comparisons.

Generally choose alectinib. Now that lorlatinib is approved, may consider this drug particularly in patients with brain mets. 

There are several right answers here. Clearly, we favor TKI therapy over chemotherapy (and ALK+ NSCLC is not an immunotherapy-responsive tumor). Crizotinib was the first but CNS coverage is its Achilles heel. Ceritinib is approved but is the least well tolerated of the bunch. Sorting out alectinib, ...